Amgen (AMGN) PT Raised to $430 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads gains as SpaceX, Super Micro results improve AI appetite
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- AI bubble about to burst? Not yet, Yardeni says
- SpaceX tops Q3 estimates as revenue surges 161% on Starlink, AI compute expansion
Tweet
Share
E-mailGet Alerts AMGN Hot Sheet
Price: $437.23 -0.39%
Rating Summary:
18 Buy, 20 Hold, 5 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 17 | New: 13
Rating Summary:
18 Buy, 20 Hold, 5 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 17 | New: 13
Join SI Premium – FREE
RBC Capital analyst Luca Issi raised the price target on Amgen (NASDAQ: AMGN) to $430.00 (from $400.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Amgen (AMGN) PT Raised to $400 at Barclays
- salesforce.com (CRM) PT Raised to $250 at DA Davidson on Braze Deal
- Amgen's tezepelumab hits Phase 3 targets in esophageal disorder trial
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
